Top Industry Leaders in the Knee Bursitis Market
Hyloris Pharmaceuticals Announces Positive Phase 2b Trial Results for Hylobact a novel biologic therapy targeting the PGNase enzyme associated with knee bursitis inflammation, demonstrated positive results in a Phase 2b trial. This could potentially lead to a new and effective treatment option for knee bursitis.
Zimmer Biomet Introduces New Knee Brace launched the QX Pro Knee Brace, designed to provide targeted compression and support for knee bursitis and other knee conditions. This new brace offers a non-invasive option for pain relief and recovery.
GE Healthcare and Arthritis Foundation Partner on Early Diagnosis Initiative collaborate on a program to raise awareness and improve early diagnosis of knee bursitis and other joint conditions. This initiative aims to encourage early intervention and prevent complications.
List of Knee Bursitis Key Companies in the Market
- Novartis AG
- Pfizer Inc
- Amgen Inc
- AVEO Pharmaceuticals Inc
- Bayer AG
- Bellicum Pharmaceuticals Inc
- MediaPharma srl
- Merck & Co., Inc
- Merrimack Pharmaceuticals Inc
- Oncolys BioPharma Inc
- United Therapeutics Corp